Bevacizumab in the treatment of ovarian cancer

Biologics: Targets and Therapy

Volumn 5, Issue , 2011, Pages 1-5

  Eskander, Ramez N ^a   Randall, Leslie M ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Angiogenesis; Bevacizumab; Molecular targeted therapy; Ovarian cancer; VEGF

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; PACLITAXEL; PLACEBO; TOPOTECAN; VASCULOTROPIN;

ADJUVANT THERAPY; CANCER RECURRENCE; CANCER RESEARCH; CAUSE OF DEATH; CELL ACTIVATION; CELL PROLIFERATION; CEREBROVASCULAR ACCIDENT; CYTOREDUCTIVE SURGERY; DIGESTIVE SYSTEM PERFORATION; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; ENDOTHELIUM CELL; FEMALE; FISTULA; GASTROINTESTINAL DISEASE; HEADACHE; HEART INFARCTION; HUMAN; HYPERTENSION; INDIVIDUALIZATION; INHIBITION KINETICS; KIDNEY DISEASE; LEUKOPENIA; MEDICAL DECISION MAKING; METABOLIC DISORDER; MOLECULAR BIOLOGY; MULTIPLE CYCLE TREATMENT; OVARY CANCER; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PROGRESSION FREE SURVIVAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TUMOR VASCULARIZATION; WOUND HEALING IMPAIRMENT;

EID: 79953208074     PISSN: 11775475     EISSN: 11775491     Source Type: Journal    
DOI: 10.2147/BTT.S13071     Document Type: Review

References (29)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer Statistics, 2010. CA Cancer J Clin. 2010;60:277-300.
2. Bookman M. Trials with impact on clinical management: first line. Int J Gynecol Cancer. 2009;19 Suppl 2:S55-S62.
3. Ozols R, Bundy B, Greer B, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2003;21:3194-3200.
4. Monk B, Choi D, Pugmire G, et al. Activity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovarian cancer. Gynecol Oncol. 2005;96:902-905.
5. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285:1182-1186.
6. Burger R. Experience with bevacizumab in the management of epithelial ovarian cancer. J Clin Oncol. 2007;25:2902-2908.
7. Randall L, Monk B. Bevacizumab toxicities and their management in ovarian cancer. Gynecol Oncol. 2010;117:497-504.
8. Ferrara N, Hillan K, Gerber H, et al. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004;3:391-400.
9. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus iri-notecan, fuorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-2342.
10. Sandler A, Gray R, Perry M, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355: 2542-2550.
11. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357: 2666-2676.
12. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007;370:2103-2111.
13. McGuire W, Hoskins W, Brady M, et al. Cyclophosphamide and c isplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996;334:1-6.
14. Markman M, Bundy B, Alberts D, et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose c arboplatin followed by intravenous paclitaxel and intraperitoneal c isplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol. 2001; 19:1001-1007.
15. Cannistra S. Evaluating new regimens in recurrent ovarian cancer: how much evidence is good enough? J Clin Oncol. 2010;28:3101-3103.
16. Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, et al. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol. 2010;28:3323-339.
17. Cannistra S. Is there a "best" choice of second-line agent in the t reatment of recurrent, potentially platinum-sensitive ovarian cancer? J Clin Oncol. 2002;20:1158-1160.
18. Kumaran G, Jayson G, Clamp A. Antiangiogenic drugs in ovarian cancer. Br J Cancer. 2009;100:1-7.
19. Byrne A, Ross L, Holash J, et al. Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model. Clin Cancer Res. 20039: 5721-5728.
20. Shen G, Ghazizadeh M, Kawanami O, et al. Prognostic significance of vascular endothelial growth factor expression in human ovarian carcinoma. Br J Cancer. 2000;83:196-203.
21. Kamba T, Tam B, Hashizume H, et al. VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol. 2006;290:H560-H576.
22. Fukumura D, Jain R: Tumor microvasculature and microenvironment: targets for anti angiogenesis and normalization. Microvasc Res. 2007; 74:72-84.
23. Burger R, Sill M, Monk B, et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007;25: 5165-5171.
24. Cannistra S, Matulonis U, Penson R, et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol. 2007;25:5180-5186.
25. Garcia A, Hirte H, Fleming G, et al. Phase II clinical trial of bevaci-zumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol. 2008;26:76-82.
26. Nimeiri H, Oza A, Morgan R, et al. Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia. Gynecol Oncol. 2008;110:49-55.
27. Auranen A, Grénman S. Radiation therapy and biological compounds for consolidation therapy in advanced ovarian cancer. Int J Gynecol Cancer. 2008;18 Suppl 1:44-46.
28. Zhu X, Wu S, Dahut W, et al. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis. 2007;49: 186-193.
29. Izzedine H, Rixe O, Billemont B, et al. Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension. Am J Kidney Dis. 2007;50: 203-218.